- Home
- MPU vs KPTI Comparison
MPU vs KPTI Comparison
Compare MPU & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPU
- KPTI
- Stock Information
- Founded
- MPU 1989
- KPTI 2008
- Country
- MPU Singapore
- KPTI United States
- Employees
- MPU N/A
- KPTI N/A
- Industry
- MPU Transportation Services
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- MPU Consumer Discretionary
- KPTI Health Care
- Exchange
- MPU Nasdaq
- KPTI Nasdaq
- Market Cap
- MPU 31.3M
- KPTI 33.6M
- IPO Year
- MPU 1998
- KPTI 2013
- Fundamental
- Price
- MPU $0.94
- KPTI $6.02
- Analyst Decision
- MPU
- KPTI Strong Buy
- Analyst Count
- MPU 0
- KPTI 5
- Target Price
- MPU N/A
- KPTI $61.00
- AVG Volume (30 Days)
- MPU 62.7K
- KPTI 154.7K
- Earning Date
- MPU 05-07-2025
- KPTI 05-07-2025
- Dividend Yield
- MPU N/A
- KPTI N/A
- EPS Growth
- MPU N/A
- KPTI N/A
- EPS
- MPU N/A
- KPTI N/A
- Revenue
- MPU $36,184,000.00
- KPTI $145,237,000.00
- Revenue This Year
- MPU N/A
- KPTI $4.87
- Revenue Next Year
- MPU N/A
- KPTI $16.29
- P/E Ratio
- MPU N/A
- KPTI N/A
- Revenue Growth
- MPU N/A
- KPTI N/A
- 52 Week Low
- MPU $0.49
- KPTI $3.51
- 52 Week High
- MPU $2.69
- KPTI $18.00
- Technical
- Relative Strength Index (RSI)
- MPU 66.38
- KPTI 62.44
- Support Level
- MPU $0.71
- KPTI $3.83
- Resistance Level
- MPU $0.95
- KPTI $6.56
- Average True Range (ATR)
- MPU 0.08
- KPTI 0.44
- MACD
- MPU 0.03
- KPTI 0.40
- Stochastic Oscillator
- MPU 96.26
- KPTI 91.47
About MPU Mega Matrix Corp.
Mega Matrix Inc formerly Mega Matrix Inc is a holding company. It operates through its two subsidiaries Mega Metaverse Corp (Mega) and JetFleet Management Corp (JMC). The Company has two business segments which are comprised of : ETH staking business and The leasing of regional aircraft to foreign and domestic regional airlines. The majority of the company's revenue is earned through Leasing business segment. The company operates in USA and Canada, Asia-Pacific, Europe, Middle East and Africa, and Latin America.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.